Korsana Biosciences disclosed a $175 million financing to develop a preclinical Alzheimer’s antibody program that uses a platform to shuttle antibodies across the blood‑brain barrier. The company plans to advance lead candidates toward IND enabling studies and leverage the funding to scale preclinical work and translational programs. Korsana’s approach resembles strategies pursued by Roche and AbbVie, which are already in clinical stages with BBB‑shuttled antibodies. The substantial raise underscores investor appetite for next‑generation delivery platforms that aim to increase CNS exposure and may accelerate comparative trials if clinical translation succeeds.